trial

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

NCTId NCT05333003
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Active Not Recruiting
Enrollment 92 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2026-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
92 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2022-05-25
Primary completion
2026-08
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Semaglutide

Sponsors

Centre for Addiction and Mental HealthLead Sponsor

Investigators

1
Margaret K Hahn, PhD, MDPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
92
Phase
NA
Primary Completion Date
2026-08
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Semaglutide
drug
lead_sponsor
Centre for Addiction and Mental Health
company
indication
Schizophrenia Spectrum Disorders
indication
Body Weight
indication
investigator
Margaret K Hahn, PhD, MD
person